Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Non-Current Deffered Revenue (2023 - 2025)

Historic Non-Current Deffered Revenue for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $95.0 million.

  • Genmab A's Non-Current Deffered Revenue rose 4179.1% to $95.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $95.0 million, marking a year-over-year increase of 4179.1%. This contributed to the annual value of $95.0 million for FY2025, which is 4179.1% up from last year.
  • Genmab A's Non-Current Deffered Revenue amounted to $95.0 million in Q4 2025, which was up 4179.1% from $67.0 million recorded in Q4 2024.
  • In the past 5 years, Genmab A's Non-Current Deffered Revenue registered a high of $95.0 million during Q4 2025, and its lowest value of $67.0 million during Q4 2024.
  • Its 3-year average for Non-Current Deffered Revenue is $77.7 million, with a median of $71.0 million in 2023.
  • As far as peak fluctuations go, Genmab A's Non-Current Deffered Revenue plummeted by 563.38% in 2024, and later skyrocketed by 4179.1% in 2025.
  • Genmab A's Non-Current Deffered Revenue (Quarter) stood at $71.0 million in 2023, then dropped by 5.63% to $67.0 million in 2024, then soared by 41.79% to $95.0 million in 2025.
  • Its last three reported values are $95.0 million in Q4 2025, $67.0 million for Q4 2024, and $71.0 million during Q4 2023.